Posted by Michael Wonder on 04 Nov 2018
Are rumours of AbbVie's Humira price cuts what they seem?
2 November 2018 - In an effort to combat competition from biosimilar adalimumab products in Europe as patents covering the reference product expired last month, AbbVie, developer of Humira, is reportedly prepared to offer a substantial discount. However, many European nations have policies that require a mandatory reduction of the reference product’s list price after biosimilar entry.
In an effort to combat new competition from biosimilar adalimumab products in Europe as patents covering the reference product expired last month, AbbVie, developer of the reference product, Humira, is reportedly prepared to offer a substantial discount.
AbbVie, whose adalimumab has never before faced biosimilar competition, seems to be preparing to protect its market share as 4 new biosimilar adalimumab products, Imraldi, Hyrimoz, Amgevita, and Hulio entered the European market last month.
